Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
ANVIMO will be available in dosages of 240 mg and 480 mg
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
For people with relapsed or refractory diffuse large B-cell lymphoma
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
